Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Helicobacter pylori Infections Overview | 7 | 1 |
| Therapeutics Development | 8 | 2 |
| Pipeline Products for Helicobacter pylori Infections Overview | 8 | 1 |
| Pipeline Products for Helicobacter pylori Infections Comparative Analysis | 9 | 1 |
| Helicobacter pylori Infections Therapeutics under Development by Companies | 10 | 1 |
| Helicobacter pylori Infections Therapeutics under Investigation by Universities/Institutes | 11 | 1 |
| Helicobacter pylori Infections Pipeline Products Glance | 12 | 3 |
| Late Stage Products | 12 | 1 |
| Clinical Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| Helicobacter pylori Infections Products under Development by Companies | 15 | 1 |
| Helicobacter pylori Infections Products under Investigation by Universities/Institutes | 16 | 1 |
| Helicobacter pylori Infections Companies Involved in Therapeutics Development | 17 | 10 |
| Daewoong Pharmaceutical Co., Ltd. | 17 | 1 |
| Debiopharm International SA | 18 | 1 |
| EpiVax, Inc. | 19 | 1 |
| Frost Biologic, Inc. | 20 | 1 |
| ImevaX GmbH | 21 | 1 |
| ImmunoBiology Limited | 22 | 1 |
| Recce Pty Ltd | 23 | 1 |
| RedHill Biopharma Ltd. | 24 | 1 |
| Sequella, Inc. | 25 | 1 |
| Sigmoid Pharma Limited | 26 | 1 |
| Helicobacter pylori Infections Therapeutics Assessment | 27 | 9 |
| Assessment by Monotherapy Products | 27 | 1 |
| Assessment by Combination Products | 28 | 1 |
| Assessment by Target | 29 | 2 |
| Assessment by Mechanism of Action | 31 | 2 |
| Assessment by Route of Administration | 33 | 1 |
| Assessment by Molecule Type | 34 | 2 |
| Drug Profiles | 36 | 21 |
| (amoxicillin sodium + omeprazole sodium + rifabutin) Drug Profile | 36 | 4 |
| Debio-1453 Drug Profile | 40 | 1 |
| DWJ-1325 Drug Profile | 41 | 1 |
| FROST-900 Drug Profile | 42 | 1 |
| Helicobacter pylori [strain Hel-305] (multivalent) vaccine Drug Profile | 43 | 1 |
| Helicobacter pylori vaccine Drug Profile | 44 | 1 |
| Helicobacter pylori vaccine Drug Profile | 45 | 1 |
| Helicobacter pylori vaccine Drug Profile | 46 | 1 |
| Helicobacter pylori vaccine Drug Profile | 47 | 1 |
| HPi-1 Drug Profile | 48 | 1 |
| IMX-101 Drug Profile | 49 | 1 |
| RECCE-327 Drug Profile | 50 | 1 |
| Small Molecules for Helicobacter Pylori Infections Drug Profile | 51 | 1 |
| Small Molecules to Inhibit DNA Synthesis for Infectious Diseases Drug Profile | 52 | 1 |
| SQ-109 Drug Profile | 53 | 4 |
| Helicobacter pylori Infections Dormant Projects | 57 | 1 |
| Helicobacter pylori Infections Product Development Milestones | 58 | 16 |
| Featured News &Press Releases | 58 | 1 |
| Apr 18, 2016: RedHill Announces Positive FDA Meeting on RHB-105 Path to Approval and Planned Confirmatory Phase III Study for H. pylori Infection | 58 | 1 |
| Mar 08, 2016: RedHill Biopharma Reports Successful Final Results of Phase III Study with RHB-105 for H. pylori Infection | 59 | 1 |
| Mar 01, 2016: RedHill Biopharma Provides Update on RHB-105 | 60 | 1 |
| Sep 08, 2015: RedHill Announces Standard-of-Care Eradication Data from the RHB-105 Phase III Study Further Supporting the Study s Positive Results | 61 | 1 |
| Aug 26, 2015: Recipharm Signs Agreement with RedHill Biopharma for Manufacturing of RHB-105 for treatment of H. pylori infection | 62 | 1 |
| Jun 15, 2015: RedHill Biopharma Successfully Meets Primary Endpoint in Phase III Study of RHB-105 for H. pylori Infection | 63 | 1 |
| Jun 15, 2015: RedHill Biopharma to Host Conference Call to Review Positive Phase III Top-Line Results with RHB-105 for H. pylori Infection | 64 | 1 |
| Jun 08, 2015: RedHill Biopharma Completes Treatment of Last Patient with RHB-105 in Phase III Study | 64 | 1 |
| Jun 03, 2015: RedHill Biopharma Provides Update on Development Pipeline and Expected Timing for RHB-105 Phase III Top-Line Results | 65 | 2 |
| May 18, 2015: RedHill Biopharma s Investor Webcast Forum Provides Update on the RHB-105 Phase III Program and Potential H. Pylori Eradication Market | 67 | 1 |
| May 07, 2015: RedHill Biopharma to Host Investor Webcast Forum Following Completion of RHB-105 Dosing in Phase III Study | 68 | 1 |
| Apr 27, 2015: RedHill Biopharma Announces Completion of Patient Enrollment in a Phase III Study of RHB-105 for H. pylori Infection | 69 | 1 |
| Apr 16, 2015: RedHill Biopharma Receives Notice of Allowance for Additional U.S. Patent for RHB-105 H. pylori Bacterial Infection Treatment | 70 | 1 |
| Nov 10, 2014: FDA Grants QIDP Fast-Track Designation To RedHill Biopharma's Phase 3 H. Pylori Drug RHB-105 | 71 | 1 |
| Aug 27, 2014: RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA | 72 | 2 |
| Appendix | 74 | 2 |
| Methodology | 74 | 1 |
| Coverage | 74 | 1 |
| Secondary Research | 74 | 1 |
| Primary Research | 74 | 1 |
| Expert Panel Validation | 74 | 1 |
| Contact Us | 74 | 1 |
| Disclaimer | 75 | 1 |